{"disease":{"id":"meningococcal","name":"Meningococcal","therapeutic_area":"","data":{},"enrichment_level":0,"last_enriched_at":null,"visit_count":0,"created_at":"2026-04-19T18:31:21.150Z","updated_at":"2026-04-19T18:39:44.960Z","meddra_pt":null,"meddra_code":null,"icd10_codes":null,"synonyms":[],"prevalence_global":null,"prevalence_us":null,"marketed_drug_count":1,"pipeline_drug_count":0,"trial_count":3},"drugs":{"marketed":[{"drug_id":"penicillin-g-sodium","indication_name":"Meningococcal Meningitis and/or Septicemia","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"PENICILLIN G SODIUM","company_name":"","drug_phase":"marketed","molecular_target":"","drug_class":"","quality_score":25,"revenue":null,"mechanism":null},{"drug_id":"rifampicin","indication_name":"Prevention of Meningococcal Meningitis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Rifadin","generic_name":"Rifampicin","company_name":"Sanofi Aventis Us","drug_phase":"marketed","molecular_target":"Solute carrier organic anion transporter family member 1A2, ATP-binding cassette sub-family G member 2, Alpha-synuclein","drug_class":"Rifamycin Antibacterial [EPC]","quality_score":10,"revenue":null,"mechanism":null},{"drug_id":"benzylpenicillin","indication_name":"Meningococcal meningitis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Penicillin G Potassium In Plastic Container","generic_name":"Benzylpenicillin","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"","drug_class":"Penicillin-class Antibacterial","quality_score":32,"revenue":null,"mechanism":""},{"drug_id":"cefotaxime","indication_name":"Meningococcal meningitis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Claforan","generic_name":"CEFOTAXIME","company_name":"Sterimax","drug_phase":"marketed","molecular_target":"","drug_class":"Cephalosporin Antibacterial","quality_score":30,"revenue":null,"mechanism":""},{"drug_id":"ampicillin","indication_name":"Meningococcal meningitis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Unasyn","generic_name":"AMPICILLIN","company_name":"Bristol-Myers Squibb","drug_phase":"marketed","molecular_target":"Transient receptor potential cation channel subfamily M member 4","drug_class":"Penicillin-class Antibacterial","quality_score":53,"revenue":null,"mechanism":""},{"drug_id":"sulfafurazole","indication_name":"Meningococcal meningitis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Azo Gantrisin","generic_name":"sulfafurazole","company_name":"Alra","drug_phase":"marketed","molecular_target":"Endothelin-1 receptor","drug_class":"Sulfonamide Antimicrobial","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"chloramphenicol","indication_name":"Meningococcal meningitis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Chlorocidin","generic_name":"CHLORAMPHENICOL","company_name":"Parkedale","drug_phase":"marketed","molecular_target":"Cytochrome P450 3A4","drug_class":"Amphenicol-class Antibacterial","quality_score":57,"revenue":null,"mechanism":""},{"drug_id":"vaccine-administration","indication_name":"Meningococcal","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Vaccine Support Cp","generic_name":"Vaccine administration","company_name":"Women and Infants Hospital of Rhode Island","drug_phase":"marketed","molecular_target":"unknown","drug_class":"vaccine","quality_score":45,"revenue":null,"mechanism":""},{"drug_id":"hospital-based-vaccination-pathway","indication_name":"Meningococcal disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Hospital-Based Vaccination Pathway","generic_name":"hospital-based-vaccination-pathway","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"various pathogens","drug_class":"vaccine","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"hospital-based-vaccination-pathway","indication_name":"Meningococcal conjugate (MenACWY)","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Hospital-Based Vaccination Pathway","generic_name":"hospital-based-vaccination-pathway","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"various pathogens","drug_class":"vaccine","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"hospital-based-vaccination-pathway","indication_name":"Meningococcal B","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Hospital-Based Vaccination Pathway","generic_name":"hospital-based-vaccination-pathway","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"various pathogens","drug_class":"vaccine","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"hospital-based-vaccination-pathway","indication_name":"Meningococcal conjugate (MenACWY) booster","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Hospital-Based Vaccination Pathway","generic_name":"hospital-based-vaccination-pathway","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"various pathogens","drug_class":"vaccine","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"hospital-based-vaccination-pathway","indication_name":"Meningococcal B (MenB) booster","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Hospital-Based Vaccination Pathway","generic_name":"hospital-based-vaccination-pathway","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"various pathogens","drug_class":"vaccine","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"hospital-based-vaccination-pathway","indication_name":"Meningococcal disease (MenACWY) booster","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Hospital-Based Vaccination Pathway","generic_name":"hospital-based-vaccination-pathway","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"various pathogens","drug_class":"vaccine","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"hospital-based-vaccination-pathway","indication_name":"Meningococcal disease (MenB) booster","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Hospital-Based Vaccination Pathway","generic_name":"hospital-based-vaccination-pathway","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"various pathogens","drug_class":"vaccine","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"hospital-based-vaccination-pathway","indication_name":"Meningococcal disease (MenACWY) booster (immunocompromised)","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Hospital-Based Vaccination Pathway","generic_name":"hospital-based-vaccination-pathway","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"various pathogens","drug_class":"vaccine","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"hospital-based-vaccination-pathway","indication_name":"Meningococcal disease (MenB) booster (immunocompromised)","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Hospital-Based Vaccination Pathway","generic_name":"hospital-based-vaccination-pathway","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"various pathogens","drug_class":"vaccine","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"hospital-based-vaccination-pathway","indication_name":"Meningococcal disease (MenACWY) booster (pregnancy)","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Hospital-Based Vaccination Pathway","generic_name":"hospital-based-vaccination-pathway","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"various pathogens","drug_class":"vaccine","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"hospital-based-vaccination-pathway","indication_name":"Meningococcal disease (MenB) booster (pregnancy)","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Hospital-Based Vaccination Pathway","generic_name":"hospital-based-vaccination-pathway","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"various pathogens","drug_class":"vaccine","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"hospital-based-vaccination-pathway","indication_name":"Meningococcal disease (MenACWY) booster (adolescent)","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Hospital-Based Vaccination Pathway","generic_name":"hospital-based-vaccination-pathway","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"various pathogens","drug_class":"vaccine","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"hospital-based-vaccination-pathway","indication_name":"Meningococcal disease (MenB) booster (adolescent)","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Hospital-Based Vaccination Pathway","generic_name":"hospital-based-vaccination-pathway","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"various pathogens","drug_class":"vaccine","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"hospital-based-vaccination-pathway","indication_name":"Meningococcal disease (MenACWY) booster (adult)","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Hospital-Based Vaccination Pathway","generic_name":"hospital-based-vaccination-pathway","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"various pathogens","drug_class":"vaccine","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"hospital-based-vaccination-pathway","indication_name":"Meningococcal disease (MenB) booster (adult)","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Hospital-Based Vaccination Pathway","generic_name":"hospital-based-vaccination-pathway","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"various pathogens","drug_class":"vaccine","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"hospital-based-vaccination-pathway","indication_name":"Meningococcal disease (MenACWY) booster (immunocompromised)","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Hospital-Based Vaccination Pathway","generic_name":"hospital-based-vaccination-pathway","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"various pathogens","drug_class":"vaccine","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"hospital-based-vaccination-pathway","indication_name":"Meningococcal disease (MenB) booster (immunocompromised)","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Hospital-Based Vaccination Pathway","generic_name":"hospital-based-vaccination-pathway","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"various pathogens","drug_class":"vaccine","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"hospital-based-vaccination-pathway","indication_name":"Meningococcal disease (MenACWY) booster (pregnancy)","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Hospital-Based Vaccination Pathway","generic_name":"hospital-based-vaccination-pathway","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"various pathogens","drug_class":"vaccine","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"hospital-based-vaccination-pathway","indication_name":"Meningococcal disease (MenB) booster (pregnancy)","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Hospital-Based Vaccination Pathway","generic_name":"hospital-based-vaccination-pathway","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"various pathogens","drug_class":"vaccine","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"hospital-based-vaccination-pathway","indication_name":"Meningococcal disease (MenACWY) booster (adolescent)","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Hospital-Based Vaccination Pathway","generic_name":"hospital-based-vaccination-pathway","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"various pathogens","drug_class":"vaccine","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"hospital-based-vaccination-pathway","indication_name":"Meningococcal disease (MenB) booster (adolescent)","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Hospital-Based Vaccination Pathway","generic_name":"hospital-based-vaccination-pathway","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"various pathogens","drug_class":"vaccine","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"ceftriaxon","indication_name":"Meningococcal meningitis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Ceftriaxon","company_name":"Centre Hospitalier Universitaire Vaudois","drug_phase":"marketed","molecular_target":"Alpha-synuclein, D-amino-acid oxidase, Penicillin-binding protein 1A","drug_class":"","quality_score":19,"revenue":null,"mechanism":null},{"drug_id":"ceftriaxon","indication_name":"Prevention of Meningococcal Meningitis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Ceftriaxon","company_name":"Centre Hospitalier Universitaire Vaudois","drug_phase":"marketed","molecular_target":"Alpha-synuclein, D-amino-acid oxidase, Penicillin-binding protein 1A","drug_class":"","quality_score":19,"revenue":null,"mechanism":null},{"drug_id":"rifampin","indication_name":"Meningococcal carrier state","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"RIFAMPIN","company_name":"","drug_phase":"marketed","molecular_target":"DNA-dependent RNA polymerase","drug_class":"Rifamycin Antibacterial [EPC]","quality_score":10,"revenue":null,"mechanism":"Rifampin inhibits DNA-dependent RNA polymerase activity in susceptible Mycobacterium tuberculosis organisms."},{"drug_id":"ceftazidime","indication_name":"Meningococcal meningitis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Fortaz","generic_name":"CEFTAZIDIME","company_name":"Pai Holdings Pharm","drug_phase":"marketed","molecular_target":"","drug_class":"ceftazidime","quality_score":10,"revenue":null,"mechanism":"Fortaz works by binding to penicillin-binding proteins on bacterial cell walls, preventing them from forming a strong cell wall and ultimately leading to bacterial cell death."},{"drug_id":"tazicef","indication_name":"Meningococcal meningitis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Fortaz","generic_name":"Ceftazidime","company_name":"Pai Holdings Pharm","drug_phase":"marketed","molecular_target":"Bacterial cell wall","drug_class":"Third-generation cephalosporin","quality_score":10,"revenue":null,"mechanism":"Bactericidal agent inhibiting bacterial cell wall synthesis with beta-lactamase resistance."},{"drug_id":"ceftriaxone","indication_name":"Meningococcal meningitis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Rocephin","generic_name":"ceftriaxone","company_name":"Generic (originally Roche)","drug_phase":"marketed","molecular_target":"Alpha-synuclein, D-amino-acid oxidase, Penicillin-binding protein 1A","drug_class":"Cephalosporin antibiotic (third-generation)","quality_score":50,"revenue":null,"mechanism":""},{"drug_id":"ceftriaxone","indication_name":"Prevention of Meningococcal Meningitis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Rocephin","generic_name":"ceftriaxone","company_name":"Generic (originally Roche)","drug_phase":"marketed","molecular_target":"Alpha-synuclein, D-amino-acid oxidase, Penicillin-binding protein 1A","drug_class":"Cephalosporin antibiotic (third-generation)","quality_score":50,"revenue":null,"mechanism":""},{"drug_id":"penicillin","indication_name":"Meningococcal meningitis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"penicillin","company_name":"Karlstad University","drug_phase":"marketed","molecular_target":"Bacterial penicillin-binding protein, Beta-lactamase, Beta-lactamase TEM","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"ceftazidim","indication_name":"Meningococcal meningitis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Ceftazidim","company_name":"Tel-Aviv Sourasky Medical Center","drug_phase":"marketed","molecular_target":"Penicillin-binding protein 1A, Penicillin-binding protein 1B, Peptidoglycan synthase FtsI","drug_class":"","quality_score":null,"revenue":null,"mechanism":null}],"pipeline":[],"offLabel":[],"totalMarketed":38,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT05873751","title":"A Study to Learn About How Trumenba Vaccine Shots Work Against Gonorrhea Infection in Teenagers and Young Adults in the United States.","phase":"","overall_status":"COMPLETED","enrollment_count":1307378,"lead_sponsor_name":"Pfizer","has_results":true},{"nct_id":"NCT03089086","title":"South Australian Meningococcal B Vaccine Herd Immunity Study","phase":"PHASE4","overall_status":"COMPLETED","enrollment_count":34489,"lead_sponsor_name":"University of Adelaide","has_results":false},{"nct_id":"NCT04664569","title":"National Bacterial Meningitis Study","phase":"","overall_status":"RECRUITING","enrollment_count":8230,"lead_sponsor_name":"Association Clinique Thérapeutique Infantile du val de Marne","has_results":false},{"nct_id":"NCT04398849","title":"Immunisation for Adolescents Against Serious Communicable Diseases (B Part of it NT)","phase":"","overall_status":"UNKNOWN","enrollment_count":7100,"lead_sponsor_name":"University of Adelaide","has_results":false},{"nct_id":"NCT01766206","title":"Safety of One Dose of Meningococcal ACWY Conjugate Vaccine in Subjects From 2 Months to 55 Years of Age in the Republic of South Korea","phase":"PHASE4","overall_status":"COMPLETED","enrollment_count":3948,"lead_sponsor_name":"GlaxoSmithKline","has_results":true},{"nct_id":"NCT04502693","title":"Effectiveness of GlaxoSmithKline Biologicals S.A's Meningococcal Group B and Combined ABCWY Vaccines in Healthy Adolescents and Young Adults","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":3657,"lead_sponsor_name":"GlaxoSmithKline","has_results":true},{"nct_id":"NCT02842853","title":"Immune Lot Consistency, Immunogenicity, and Safety of an Investigational Quadrivalent Meningococcal Conjugate Vaccine","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":3344,"lead_sponsor_name":"Sanofi Pasteur, a Sanofi Company","has_results":true},{"nct_id":"NCT04061382","title":"Sero-epidemiological Survey of England in 2019/2020 - COVID-19","phase":"","overall_status":"COMPLETED","enrollment_count":2963,"lead_sponsor_name":"University of Oxford","has_results":false},{"nct_id":"NCT03673462","title":"Safety of a Quadrivalent Meningococcal Conjugate Vaccine Administered Concomitantly With Routine Pediatric Vaccines in Healthy Infants and Toddlers","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":2797,"lead_sponsor_name":"Sanofi Pasteur, a Sanofi Company","has_results":true},{"nct_id":"NCT01461980","title":"A Clinical Trial to Study the Safety, Tolerance and Immunogenic Response to MCV4, Tdap and Bivalent rLP2086 Vaccine When Given at the Same Time to Children Between the Ages of 10 Through 12 Years of Age","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":2648,"lead_sponsor_name":"Pfizer","has_results":true},{"nct_id":"NCT03537508","title":"Immunogenicity and Safety of a Quadrivalent Meningococcal Conjugate Vaccine When Administered Concomitantly With Routine Pediatric Vaccines in Healthy Infants and Toddlers in the US","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":2627,"lead_sponsor_name":"Sanofi Pasteur, a Sanofi Company","has_results":true},{"nct_id":"NCT01461993","title":"A Clinical Trial to Study the Safety, Tolerance and Immunogenic Response to Gardasil and Bivalent rLP2086 Vaccine When Given at the Same Time to Children Between the Ages of 11 and 17","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":2499,"lead_sponsor_name":"Pfizer","has_results":true},{"nct_id":"NCT04440163","title":"MenABCWY Noninferiority Study in Healthy Participants ≥10 to <26 Years of Age","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":2431,"lead_sponsor_name":"Pfizer","has_results":true},{"nct_id":"NCT01144663","title":"Immunogenicity and Safety of Meningococcal Vaccine GSK 134612 Co-administered With Pneumococcal and DTPa-HBV-IPV/Hib Vaccines","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":2095,"lead_sponsor_name":"GlaxoSmithKline","has_results":true},{"nct_id":"NCT03964012","title":"Study to Assess Immunegnicity & Safety of Pentavalent Meningococcal Vaccine (NmCV-5)","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":1800,"lead_sponsor_name":"Serum Institute of India Pvt. Ltd.","has_results":false},{"nct_id":"NCT02199691","title":"Immunogenicity and Safety of an Investigational Quadrivalent Meningococcal Conjugate Vaccine in Healthy Adolescents","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":1715,"lead_sponsor_name":"Sanofi Pasteur, a Sanofi Company","has_results":true},{"nct_id":"NCT01299480","title":"A Trial To Assess The Safety, Tolerability, And Immunogenicity Of Rlp2086 Vaccine When Administered In Either 2- Or 3-Dose Regimens In Healthy Subjects Aged ≥11 To <19 Years","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":1714,"lead_sponsor_name":"Pfizer","has_results":true},{"nct_id":"NCT03433482","title":"A Study to Investigate the Safety and Immunogenicity of Different Formulations of GSK Biologicals' Meningococcal ACWY Conjugate Vaccine (GSK3536820A and Menveo) Administered to Healthy Adolescents and Young Adults 10 to 40 Years of Age","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":1707,"lead_sponsor_name":"GlaxoSmithKline","has_results":true},{"nct_id":"NCT03547271","title":"Immunogenicity and Safety Study of a Quadrivalent Meningococcal Conjugate Vaccine When Co-administered With Routine Pediatric Vaccines in Healthy Infants and Toddlers in Europe","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":1660,"lead_sponsor_name":"Sanofi Pasteur, a Sanofi Company","has_results":true},{"nct_id":"NCT04358731","title":"Study to Evaluate the Lot to Lot Consistency of SIIPL Meningococcal ACYWX Conjugate Vaccine and to Compare Its Safety and Immunogenicity With That of Licensed Meningococcal ACWY Vaccine Menactra® in Healthy Individuals 18-85 Years of Age","phase":"PHASE2, PHASE3","overall_status":"COMPLETED","enrollment_count":1640,"lead_sponsor_name":"Serum Institute of India Pvt. Ltd.","has_results":false},{"nct_id":"NCT03135834","title":"A Trial to Describe the Immunogenicity and Safety of 2 Doses of Bivalent rLP2086 (Trumenba) and a Pentavalent Meningococcal Vaccine in Healthy Subjects >=10 to <26 Years of Age.","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":1610,"lead_sponsor_name":"Pfizer","has_results":true},{"nct_id":"NCT07135986","title":"Immunogenicity and Safety Study of an Investigational Quadrivalent Meningococcal Conjugate Vaccine Administered in Healthy Children and Adolescents in China","phase":"PHASE3","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":1602,"lead_sponsor_name":"Sanofi","has_results":false},{"nct_id":"NCT00614614","title":"Immuno,Safety of GSK Vaccine 134612 Given at Age of 12-15 Months 15-18 Months Post-priming With GSK Vaccine 792014","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":1558,"lead_sponsor_name":"GlaxoSmithKline","has_results":true},{"nct_id":"NCT05794230","title":"Study of a Quadrivalent Meningococcal Conjugate Vaccine (MenACYW Conjugate Vaccine) Given With Routine Pediatric Vaccines in Healthy Infants and Toddlers in India and the Republic of South Africa","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":1528,"lead_sponsor_name":"Sanofi Pasteur, a Sanofi Company","has_results":false},{"nct_id":"NCT00514904","title":"Non-Inferiority of Meningococcal Vaccine GSK134612 Versus Mencevax™ in 2-10 Year Old Subjects","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":1504,"lead_sponsor_name":"GlaxoSmithKline","has_results":true},{"nct_id":"NCT04886154","title":"A Study on the Safety, Effectiveness and Immune Response of Meningococcal Combined ABCWY Vaccine in Healthy Adolescents and Adults","phase":"PHASE1, PHASE2","overall_status":"COMPLETED","enrollment_count":1440,"lead_sponsor_name":"GlaxoSmithKline","has_results":true},{"nct_id":"NCT00453986","title":"Lot Consistency, Immuno, Safety of Meningococcal Vaccine GSK134612 Given With Fluarix™ to 18-55 Year-Old Adults","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":1352,"lead_sponsor_name":"GlaxoSmithKline","has_results":true},{"nct_id":"NCT03378258","title":"Petechiae In Children (PIC) Study: Defining A Clinical Decision Rule for The Management Of Fever and Non-Blanching Rashes In Children Including The Role Of Point Of Care Testing For Procalcitonin & Neisseria Meningitidis DNA.","phase":"","overall_status":"COMPLETED","enrollment_count":1329,"lead_sponsor_name":"Belfast Health and Social Care Trust","has_results":false},{"nct_id":"NCT04143061","title":"Immunogenicity and Safety of an Investigational Quadrivalent Meningococcal Conjugate Vaccine in Healthy Adults, Adolescents, Children, and Toddlers in India and Healthy Adolescents and Children in the Republic of South Africa","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":1328,"lead_sponsor_name":"Sanofi Pasteur, a Sanofi Company","has_results":true},{"nct_id":"NCT02864927","title":"Postmarketing Surveillance Study for Use of Menactra® in the Republic of Korea","phase":"PHASE4","overall_status":"COMPLETED","enrollment_count":1311,"lead_sponsor_name":"Sanofi Pasteur, a Sanofi Company","has_results":false},{"nct_id":"NCT01755689","title":"Immunogenicity and Safety Study of GlaxoSmithKline (GSK) Biologicals' Meningococcal Vaccine With or Without Co-administration of Cervarix and Boostrix in Female Adolescents and Young Adults","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":1300,"lead_sponsor_name":"GlaxoSmithKline","has_results":true},{"nct_id":"NCT04707391","title":"Immunogenicity and Safety Study of GSK's MenABCWY Vaccine in Healthy Adolescents and Adults Previously Primed With MenACWY Vaccine","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":1250,"lead_sponsor_name":"GlaxoSmithKline","has_results":true},{"nct_id":"NCT06128733","title":"Study of an Investigational Pentavalent Meningococcal ABCYW Vaccine in Adults and Adolescents","phase":"PHASE1, PHASE2","overall_status":"COMPLETED","enrollment_count":1215,"lead_sponsor_name":"Sanofi Pasteur, a Sanofi Company","has_results":false},{"nct_id":"NCT05252715","title":"Immunogenicity and Safety of Meningococcal ACYW135 Polysaccharide Conjugate Vaccine in Volunteers Aged From 3 to 5 Months","phase":"PHASE3","overall_status":"UNKNOWN","enrollment_count":1200,"lead_sponsor_name":"Beijing Zhifei Lvzhu Biopharmaceutical Co., Ltd","has_results":false},{"nct_id":"NCT03621670","title":"Safety and Immunogenicity of GSK Meningococcal Group B Vaccine and 13-valent Pneumococcal Vaccine Administered Concomitantly With Routine Infant Vaccines to Healthy Infants","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":1196,"lead_sponsor_name":"GlaxoSmithKline","has_results":true},{"nct_id":"NCT03205371","title":"Immunogenicity and Safety of a Meningococcal Conjugate Vaccine Given Concomitantly With Other Vaccines in Toddlers","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":1183,"lead_sponsor_name":"Sanofi Pasteur, a Sanofi Company","has_results":true},{"nct_id":"NCT01154088","title":"Immunogenicity and Safety of Meningococcal Vaccine GSK 134612 Versus Mencevax™ ACWY in Healthy 18-25 Year Olds","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":1170,"lead_sponsor_name":"GlaxoSmithKline","has_results":true},{"nct_id":"NCT02212457","title":"Trial to Assess Immunogenicity and Safety of GlaxoSmithKline (GSK) Biologicals' Meningococcal ABCWY Vaccine as Compared to Meningococcal B Vaccine in Adolescents","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":1063,"lead_sponsor_name":"GlaxoSmithKline","has_results":true},{"nct_id":"NCT00464815","title":"Non-Inferiority of Meningococcal Vaccine GSK134612 Versus Mencevax™ in 11-17 Year-Old Subjects","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":1025,"lead_sponsor_name":"GlaxoSmithKline","has_results":true},{"nct_id":"NCT03493919","title":"A Sourcing Study to Collect Human Blood Samples From Healthy Adults","phase":"PHASE4","overall_status":"COMPLETED","enrollment_count":1021,"lead_sponsor_name":"GlaxoSmithKline","has_results":true},{"nct_id":"NCT01165242","title":"Immunogenicity and Safety Study of GSK Biologicals' Meningococcal Vaccine GSK 134612 Versus Menactra® in Healthy Adolescents/Adults","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":1013,"lead_sponsor_name":"GlaxoSmithKline","has_results":true},{"nct_id":"NCT01808365","title":"N. Meningitidis Carriage Study","phase":"","overall_status":"COMPLETED","enrollment_count":1000,"lead_sponsor_name":"GlaxoSmithKline","has_results":false},{"nct_id":"NCT00474266","title":"Safety & Immunogenicity Study of Meningococcal Vaccine GSK134612 Given With Priorix-Tetra™ to 12-23 Month-Old Children","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":1000,"lead_sponsor_name":"GlaxoSmithKline","has_results":true},{"nct_id":"NCT03077438","title":"Study of an Investigational Quadrivalent Meningococcal Conjugate Vaccine Administered in Children Aged 2 to 9 Years","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":1000,"lead_sponsor_name":"Sanofi Pasteur, a Sanofi Company","has_results":true},{"nct_id":"NCT03652610","title":"A Study to Investigate the Safety and Immunogenicity of Different Formulations of GSK Biologicals' Meningococcal ACWY Conjugate Vaccine (GSK3536820A and Menveo) Administered to Healthy Adults 18 to 40 Years of Age","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":996,"lead_sponsor_name":"GlaxoSmithKline","has_results":true},{"nct_id":"NCT03691610","title":"Immunogenicity and Safety Study of a Quadrivalent Meningococcal Conjugate Vaccine Administered Concomitantly With Routine Pediatric Vaccines in Healthy Infants and Toddlers","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":950,"lead_sponsor_name":"Sanofi Pasteur, a Sanofi Company","has_results":true},{"nct_id":"NCT04318548","title":"Study to Assess the Safety and Immunogenicity of GSK Meningococcal Group B Vaccine When Administered Concomitantly With GSK Meningococcal MenACWY Conjugate Vaccine in Healthy Subjects of 16-18 Years of Age","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":945,"lead_sponsor_name":"GlaxoSmithKline","has_results":true},{"nct_id":"NCT02955797","title":"Immunogenicity and Safety of an Investigational Quadrivalent Meningococcal Conjugate Vaccine in Toddlers","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":918,"lead_sponsor_name":"Sanofi Pasteur, a Sanofi Company","has_results":true},{"nct_id":"NCT02842866","title":"Immunogenicity and Safety of an Investigational Quadrivalent Meningococcal Conjugate Vaccine in Adults 56 Years and Older","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":907,"lead_sponsor_name":"Sanofi Pasteur, a Sanofi Company","has_results":true},{"nct_id":"NCT00454909","title":"Immunogenicity and Safety of Meningococcal Vaccine GSK134612 vs. Menactra® in Healthy Adolescent/Adults Aged 10-25 Years.","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":873,"lead_sponsor_name":"GlaxoSmithKline","has_results":true}],"total":50},"guidelines":[],"source":"Drug Landscape verified database"}